• Je něco špatně v tomto záznamu ?

Selective Disruption of Respiratory Supercomplexes as a New Strategy to Suppress Her2(high) Breast Cancer

K. Rohlenova, K. Sachaphibulkij, J. Stursa, A. Bezawork-Geleta, J. Blecha, B. Endaya, L. Werner, J. Cerny, R. Zobalova, J. Goodwin, T. Spacek, E. Alizadeh Pesdar, B. Yan, MN. Nguyen, M. Vondrusova, M. Sobol, P. Jezek, P. Hozak, J. Truksa, J....

. 2017 ; 26 (2) : 84-103. [pub] 20160822

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031599

AIMS: Expression of the HER2 oncogene in breast cancer is associated with resistance to treatment, and Her2 may regulate bioenergetics. Therefore, we investigated whether disruption of the electron transport chain (ETC) is a viable strategy to eliminate Her2(high) disease. RESULTS: We demonstrate that Her2(high) cells and tumors have increased assembly of respiratory supercomplexes (SCs) and increased complex I-driven respiration in vitro and in vivo. They are also highly sensitive to MitoTam, a novel mitochondrial-targeted derivative of tamoxifen. Unlike tamoxifen, MitoTam efficiently suppresses experimental Her2(high) tumors without systemic toxicity. Mechanistically, MitoTam inhibits complex I-driven respiration and disrupts respiratory SCs in Her2(high) background in vitro and in vivo, leading to elevated reactive oxygen species production and cell death. Intriguingly, higher sensitivity of Her2(high) cells to MitoTam is dependent on the mitochondrial fraction of Her2. INNOVATION: Oncogenes such as HER2 can restructure ETC, creating a previously unrecognized therapeutic vulnerability exploitable by SC-disrupting agents such as MitoTam. CONCLUSION: We propose that the ETC is a suitable therapeutic target in Her2(high) disease. Antioxid. Redox Signal. 26, 84-103.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031599
003      
CZ-PrNML
005      
20231121141029.0
007      
ta
008      
171025s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1089/ars.2016.6677 $2 doi
035    __
$a (PubMed)27392540
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rohlenová, Kateřina $d 1985- $7 xx0225179 $u Institute of Biotechnology , Czech Academy of Sciences, BIOCEV, Vestec, Prague-West, Czech Republic .
245    10
$a Selective Disruption of Respiratory Supercomplexes as a New Strategy to Suppress Her2(high) Breast Cancer / $c K. Rohlenova, K. Sachaphibulkij, J. Stursa, A. Bezawork-Geleta, J. Blecha, B. Endaya, L. Werner, J. Cerny, R. Zobalova, J. Goodwin, T. Spacek, E. Alizadeh Pesdar, B. Yan, MN. Nguyen, M. Vondrusova, M. Sobol, P. Jezek, P. Hozak, J. Truksa, J. Rohlena, LF. Dong, J. Neuzil,
520    9_
$a AIMS: Expression of the HER2 oncogene in breast cancer is associated with resistance to treatment, and Her2 may regulate bioenergetics. Therefore, we investigated whether disruption of the electron transport chain (ETC) is a viable strategy to eliminate Her2(high) disease. RESULTS: We demonstrate that Her2(high) cells and tumors have increased assembly of respiratory supercomplexes (SCs) and increased complex I-driven respiration in vitro and in vivo. They are also highly sensitive to MitoTam, a novel mitochondrial-targeted derivative of tamoxifen. Unlike tamoxifen, MitoTam efficiently suppresses experimental Her2(high) tumors without systemic toxicity. Mechanistically, MitoTam inhibits complex I-driven respiration and disrupts respiratory SCs in Her2(high) background in vitro and in vivo, leading to elevated reactive oxygen species production and cell death. Intriguingly, higher sensitivity of Her2(high) cells to MitoTam is dependent on the mitochondrial fraction of Her2. INNOVATION: Oncogenes such as HER2 can restructure ETC, creating a previously unrecognized therapeutic vulnerability exploitable by SC-disrupting agents such as MitoTam. CONCLUSION: We propose that the ETC is a suitable therapeutic target in Her2(high) disease. Antioxid. Redox Signal. 26, 84-103.
650    _2
$a protinádorové látky $x chemie $x farmakologie $7 D000970
650    _2
$a biologické markery $7 D015415
650    _2
$a nádory prsu $x farmakoterapie $x metabolismus $x patologie $7 D001943
650    _2
$a buněčná smrt $x účinky léků $7 D016923
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a buněčné dýchání $x účinky léků $7 D019069
650    _2
$a elektronový transportní řetězec $x antagonisté a inhibitory $x chemie $x metabolismus $7 D045222
650    _2
$a respirační komplex I $x antagonisté a inhibitory $x chemie $x metabolismus $7 D042967
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a inhibiční koncentrace 50 $7 D020128
650    _2
$a membránový potenciál mitochondrií $x účinky léků $7 D053078
650    _2
$a mitochondrie $x účinky léků $x metabolismus $7 D008928
650    _2
$a molekulární modely $7 D008958
650    _2
$a molekulární konformace $7 D008968
650    _2
$a cílená molekulární terapie $7 D058990
650    _2
$a vazba proteinů $7 D011485
650    _2
$a reaktivní formy kyslíku $x metabolismus $7 D017382
650    _2
$a receptor erbB-2 $x antagonisté a inhibitory $x metabolismus $7 D018719
650    _2
$a tamoxifen $x farmakologie $7 D013629
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sachaphibulkij, Karishma $u School of Medical Science, Griffith University , Southport, Australia .
700    1_
$a Stursa, Jan $u School of Medical Science, Griffith University , Southport, Australia . 3 Prague Institute of Chemical Technology , Prague, Czech Republic . 4 Biomedical Research Center, University Hospital , Hradec Kralove, Czech Republic .
700    1_
$a Bezawork-Geleta, Ayenachew $u School of Medical Science, Griffith University , Southport, Australia .
700    1_
$a Blecha, Jan $u Institute of Biotechnology , Czech Academy of Sciences, BIOCEV, Vestec, Prague-West, Czech Republic .
700    1_
$a Endaya, Berwini $u School of Medical Science, Griffith University , Southport, Australia .
700    1_
$a Werner, Lukas $u Biomedical Research Center, University Hospital , Hradec Kralove, Czech Republic .
700    1_
$a Cerny, Jiri $u Institute of Biotechnology , Czech Academy of Sciences, BIOCEV, Vestec, Prague-West, Czech Republic .
700    1_
$a Zobalová, Renata $u Institute of Biotechnology , Czech Academy of Sciences, BIOCEV, Vestec, Prague-West, Czech Republic . 2 School of Medical Science, Griffith University , Southport, Australia . $7 xx0310352
700    1_
$a Goodwin, Jacob $u School of Medical Science, Griffith University , Southport, Australia .
700    1_
$a Spacek, Tomas $u Institute of Physiology , Prague, Czech Republic .
700    1_
$a Alizadeh Pesdar, Elham $u School of Medical Science, Griffith University , Southport, Australia . $7 gn_A_00004310
700    1_
$a Yan, Bing $u School of Medical Science, Griffith University , Southport, Australia .
700    1_
$a Nguyen, Maria Nga $u School of Medical Science, Griffith University , Southport, Australia .
700    1_
$a Vondrusova, Magdalena $u Institute of Biotechnology , Czech Academy of Sciences, BIOCEV, Vestec, Prague-West, Czech Republic .
700    1_
$a Sobol, Margaryta $u Institute of Molecular Genetics , Czech Academy of Sciences, Prague, Czech Republic .
700    1_
$a Jezek, Petr $u Institute of Physiology , Prague, Czech Republic .
700    1_
$a Hozak, Pavel $u Institute of Molecular Genetics , Czech Academy of Sciences, Prague, Czech Republic .
700    1_
$a Truksa, Jaroslav $u Institute of Biotechnology , Czech Academy of Sciences, BIOCEV, Vestec, Prague-West, Czech Republic .
700    1_
$a Rohlena, Jakub $u Institute of Biotechnology , Czech Academy of Sciences, BIOCEV, Vestec, Prague-West, Czech Republic .
700    1_
$a Dong, Lan-Feng $u School of Medical Science, Griffith University , Southport, Australia .
700    1_
$a Neuzil, Jiri $u Institute of Biotechnology , Czech Academy of Sciences, BIOCEV, Vestec, Prague-West, Czech Republic . 2 School of Medical Science, Griffith University , Southport, Australia .
773    0_
$w MED00006026 $t Antioxidants & redox signaling $x 1557-7716 $g Roč. 26, č. 2 (2017), s. 84-103
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27392540 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20231121141026 $b ABA008
999    __
$a ok $b bmc $g 1255192 $s 992626
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 26 $c 2 $d 84-103 $e 20160822 $i 1557-7716 $m Antioxidants & redox signaling $n Antioxid Redox Signal $x MED00006026
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Možnosti archivace